Pharmaceuticals Segment was Sanofi’s largest revenue line in fiscal 2025, bringing in $22.18B of $42.95B (52%).
| Products and services [axis] | FY 2017 | FY 2024 | FY 2025 |
|---|---|---|---|
| Pharmaceuticals Segment | $41.08B | $22.18B | |
| Primary Care | — | — | |
| Specialty Care | — | — | |
| Dupixent | — | $11.54B | |
| Lantus | — | — | |
| Launches | — | $3.36B | |
| Generics | — | — | |
| Lovenox | — | — | |
| Plavix | — | — | |
| Influenza Vaccines | — | $1.33B | |
| Altuviiio | — | $979.00M | |
| Aubagio | — | $135.00M | |
| Toujeo | — | — | |
| Myozyme/Lumizyme | — | — | |
| Cerezyme | — | — | |
| Rsv Vaccines (Beyfortus) | — | $723.00M | |
| Fabrazyme | — | — | |
| Meningitis, Travel & Endemics Vaccines | — | $720.00M | |
| Polio Pertussis Hib Vaccines | — | $632.00M | |
| Rezurock | — | $425.00M | |
| Nexviazyme | — | $393.00M | |
| Jevtana | — | — | |
| Multaq | — | — | |
| Sarclisa | — | $244.00M | |
| Praluent | — | — | |
| Cablivi | — | $143.00M | |
| Xenpozyme | — | $95.00M | |
| Tzield | — | $59.00M | |
| Industrial Sales | — | $1.00M | |
| Total | $41.08B | $42.95B |
Sanofi brought in $42.95B from its 16 revenue lines in fiscal 2025, the year ended December 31, 2025. Sanofi regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $41.08B. Pharmaceuticals Segment was the largest at $22.18B (51.6%), ahead of Dupixent at $11.54B (26.9%) and Launches at $3.36B (7.8%). The other 13 revenue lines brought in $5.88B combined.
Sanofi began breaking out Launches in fiscal 2025, Influenza Vaccines in fiscal 2025, Altuviiio in fiscal 2025 and Rsv Vaccines (Beyfortus) in fiscal 2025.
Us was Sanofi’s largest region in fiscal 2025, bringing in $22.18B of $43.63B (51%).
| Geography | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Us | $17.26B | $19.99B | $22.18B | ||||||
| Usa | — | — | — | ||||||
| Other Countries | — | — | — | ||||||
| North America | — | — | — | ||||||
| Other | $11.74B | $12.07B | $12.28B | ||||||
| Europe | $8.82B | $9.03B | $9.17B | ||||||
| Total | $37.82B | $41.08B | $43.63B |
Sanofi brought in $43.63B from its three regions in fiscal 2025, the year ended December 31, 2025. That was up 6.2% from $41.08B in fiscal 2024. Us was the largest at $22.18B (50.8%), ahead of Other at $12.28B (28.2%) and Europe at $9.17B (21.0%).
Compared with fiscal 2024, Us grew fastest, up 11.0% to $22.18B. Every region above 2% of revenue grew. From fiscal 2023 to 2025, combined revenue from these regions grew from $37.82B to $43.63B, a compound annual growth rate of 7.4%. Us' share of the total rose from 45.6% to 50.8%.
Previously Stated was Sanofi’s largest revenue line in fiscal 2016, bringing in $33.82B of $33.80B (100%).
| Retrospective application and retrospective restatement [axis] | FY 2016 |
|---|---|
| Previously Stated | $33.82B |
| Increase (Decrease) Due To Application Of Ifrs 15 | -$12.00M |
| Impact Of Ifrs15 | -$12.00M |
| Total | $33.80B |
Sanofi brought in $33.80B from its three revenue lines in fiscal 2016, the year ended December 31, 2016. Previously Stated was the largest at $33.82B (100.1%).
The total is net of Increase (Decrease) Due To Application Of Ifrs 15, which took $12.00M off revenue in fiscal 2016.
Sanofi (SNY) reports its revenue by products and services [axis], by geography and by retrospective application and retrospective restatement [axis]. In fiscal 2025, Pharmaceuticals Segment was its largest revenue line, bringing in $22.18B (51.6% of the total), followed by Dupixent at $11.54B (26.9%).
Pharmaceuticals Segment was Sanofi's largest revenue line in fiscal 2025, bringing in $22.18B, or 51.6% of the $42.95B total across its 16 revenue lines.
Us was Sanofi's largest region in fiscal 2025, bringing in $22.18B, or 50.8% of the $43.63B total across its three regions.
Among Sanofi's regions that make up at least 2% of revenue, Us grew fastest in fiscal 2025, up 11.0% from $19.99B to $22.18B.
Every figure comes from Sanofi's annual financial filings, as reported. Each line keeps the name Sanofi gives it, and years follow its fiscal calendar.
Sanofi's revenue by products and services [axis] goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.